+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults



CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults



Allergy, Asthma, and Clinical Immunology 9(1): 24-24



Atopic dermatitis (AD) is a condition frequently encountered in medical practices across the country. Arming ourselves with appropriate and safe treatment modalities to provide relief for this chronic and relapsing inflammatory condition is of utmost importance to our patients and their families. Utilizing topical calcineurin inhibitors (TCIs) for the treatment of AD not responsive to high-potency corticosteroids, or low-potency corticosteroids and localized to the face, eyelids, and skin folds of patients >2 years, is reasonable to include in common practice. Despite the FDA's Black Box warning, to date no evidence has been published linking the TCIs to an increased incidence of malignancy in either children or adults that establishes causation. The Canadian Society of Allergy and Clinical Immunology (CSACI) therefore recognizes that the benefits of TCIs should be carefully weighed with the theoretical risks in advising patients, and acknowledges that long-term studies remain in progress. The safety and efficacy of topical tacrolimus and pimecrolimus should therefore be considered when treating children and adults with AD in Canadian allergy and immunology practices.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036968581

Download citation: RISBibTeXText

PMID: 23837743

DOI: 10.1186/1710-1492-9-24


Related references

Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. PharmacoTherapy 27(7): 1020-1028, 2007

The treatment of atopic dermatitis in adults with topical calcineurin inhibitors. Der Hautarzt; Zeitschrift für Dermatologie Venerologie und verwandte Gebiete 54(5): 424-431, 2003

A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. Medgenmed 8(4): 8, 2006

Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Current Allergy and Asthma Reports 6(4): 270-274, 2006

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 211(2): 174-187, 2005

Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. Bmc Pediatrics 16: 75, 2016

Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology 6(2): 65-77, 2005

Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues. Journal der Deutschen Dermatologischen Gesellschaft 10(3): 167-172, 2012

Role of topical calcineurin inhibitors on atopic dermatitis of children. Current Medicinal Chemistry 14(14): 1579-1591, 2007

Role of Topical Calcineurin Inhibitors on Atopic Dermatitis of Children. Current Medicinal Chemistry 14(14): 1579-1591, 2007

Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis 26(3): 122-132, 2016

Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema. British Journal of Dermatology 161(2): 219-220, 2009

Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. American Journal of Therapeutics 16(3): 264-273, 2009

Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Current Medical Research and Opinion 24(4): 985-994, 2008

Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis. American Journal of Clinical Dermatology 5(4): 267-279, 2004